Bayer, Onyx cancer drug shows modest improvement in survival

A colorectal cancer drug under development by Bayer HealthCare modestly improved overall survival in some of the sickest patients in a late-stage trial, partner Onyx Pharmaceuticals Inc.? ? Onyx Pharmaceuticals Inc. Latest from The Business Journals Bayer, Onyx cancer drug shows modest improvement in survivalCresa opens East Bay office; more growth to comeDealmakers seek to reset biotech clock Follow this company said Tuesday, and Bayer will seek Food and Drug Administration approval of the drug this year.

The median overall survival of patients on experimental regorafenib was 6.4 months. That compares to five months for patients who were given a placebo.

Onyx called the finding, released at the American Society of Clinical Oncology's gastrointestinal cancer meeting in San Francisco, statistically significant. But critics appeared less than wowed by the small improvement.

The companies also said the 760-patient study showed that patients on regorafenib had a better median progression-free survival rate than those on placebo -- 1.9 months versus 1.7 months -- and a better disease control rate.

Source: http://feeds.bizjournals.com/~r/vertical_38/~3/f6CACCRVFvE/bayer-onyx-cancer-drug-shows-modest.html

dina manzo once upon a time once upon a time demarco murray teresa giudice red ribbon week much ado about nothing